{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T23:44:33Z","timestamp":1786146273504,"version":"build-2736575974"},"reference-count":18,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clbc.2026.07.006","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:44:13Z","timestamp":1783698253000},"page":"165-171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Value of Estrogen Receptors Versus Progesterone Receptors in Early Breast Cancer: An Analysis of Clinical and Translational Data (2004-2026)"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6539-5432","authenticated-orcid":false,"given":"Noureddine","family":"Samai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aymen","family":"Berremdani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.clbc.2026.07.006_bib0001","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1200\/JCO.2010.30.3677","article-title":"Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial","volume":"29","author":"Bartlett","year":"2011","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.clbc.2026.07.006_bib0002","doi-asserted-by":"crossref","first-page":"7721","DOI":"10.1200\/JCO.2005.09.004","article-title":"Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy","volume":"23","author":"Cui","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7560","key":"10.1016\/j.clbc.2026.07.006_bib0003","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nature14583","article-title":"Progesterone receptor modulates estrogen receptor-alpha action in breast cancer","volume":"523","author":"Mohammed","year":"2015","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.clbc.2026.07.006_bib0004","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3462","article-title":"Estrogen receptor negative\/progesterone receptor positive breast cancer is not a reproducible subtype","volume":"15","author":"Hefti","year":"2013","journal-title":"Breast Cancer Res"},{"issue":"2","key":"10.1016\/j.clbc.2026.07.006_bib0005","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4048\/jbc.2015.18.2.149","article-title":"Differences in clinical outcomes between luminal A and B type breast cancers according to the St. Gallen Consensus 2013","volume":"18","author":"Ahn","year":"2015","journal-title":"J Breast Cancer"},{"issue":"2","key":"10.1016\/j.clbc.2026.07.006_bib0006","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1200\/JCO.2012.43.4134","article-title":"Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer","volume":"31","author":"Prat","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.07.006_bib0007","article-title":"The prognosis of single hormone receptor-positive breast cancer stratified by HER2 status","volume":"11","author":"Zhao","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clbc.2026.07.006_bib0008","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12885-015-1121-4","article-title":"Poor prognosis of single hormone receptor-positive breast cancer: similar outcome as triple-negative breast cancer","volume":"15","author":"Bae","year":"2015","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.clbc.2026.07.006_bib0009","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10549-015-3612-z","article-title":"Predictive value and clinical utility of centrally-assessed ER, PgR and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials","volume":"154","author":"Regan","year":"2015","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.clbc.2026.07.006_bib0010","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4048\/jbc.2017.20.2.160","article-title":"Prognostic impact of progesterone receptor status in Chinese estrogen receptor positive invasive breast cancer patients","volume":"20","author":"Yao","year":"2017","journal-title":"J Breast Cancer"},{"issue":"22","key":"10.1016\/j.clbc.2026.07.006_bib0011","doi-asserted-by":"crossref","first-page":"8184","DOI":"10.1158\/0008-5472.CAN-04-2045","article-title":"Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer","volume":"64","author":"Leu","year":"2004","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.006_bib0012","doi-asserted-by":"crossref","first-page":"R6","DOI":"10.1186\/bcr1639","article-title":"Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients","volume":"9","author":"Dunnwald","year":"2007","journal-title":"Breast Cancer Res"},{"issue":"13","key":"10.1016\/j.clbc.2026.07.006_bib0013","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15133435","article-title":"Progesterone receptor expression level predicts prognosis of estrogen receptor-positive\/HER2-negative young breast cancer: a single-center prospective cohort study","volume":"15","author":"Kwak","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.clbc.2026.07.006_bib0014","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2147\/BCTT.S512760","article-title":"Late breast cancer recurrence prediction: the role of CTS5 and progesterone receptor status","volume":"17","author":"Carvalho","year":"2025","journal-title":"Breast Cancer Targets Ther"},{"issue":"4","key":"10.1016\/j.clbc.2026.07.006_bib0015","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3390\/cancers17040693","article-title":"The impact of progesterone receptor status on survival outcomes in metastatic breast cancer patients treated with first-line CDK4\/6 inhibitors","volume":"17","author":"Guliyev","year":"2025","journal-title":"Cancers"},{"issue":"32","key":"10.1016\/j.clbc.2026.07.006_bib0016","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1200\/JCO.2010.31.2835","article-title":"Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer","volume":"29","author":"Cuzick","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9561","key":"10.1016\/j.clbc.2026.07.006_bib0017","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0140-6736(07)60200-1","article-title":"Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial","volume":"369","author":"Coombes","year":"2007","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.clbc.2026.07.006_bib0018","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/bjc.2013.756","article-title":"Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study","volume":"110","author":"Purdie","year":"2014","journal-title":"Br J Cancer"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926001059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926001059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T23:31:17Z","timestamp":1786145477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820926001059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1526820926001059"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2026.07.006","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Value of Estrogen Receptors Versus Progesterone Receptors in Early Breast Cancer: An Analysis of Clinical and Translational Data (2004-2026)","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2026.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}